Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Zev Wainberg, MD, regarding bemarituzumab as a single agent in the treatment of gastric cancer

Tags: ASCO GI Conference CoverageEsophagealStomach (Gastric) Cancer

Published: 16 January 2021

Recent Videos: Esophageal

video

Rachna Shroff, MD, elaborates on newly approved targeted therapies in esophagogastric cancer

Dr. Shroff, Medical Director, Clinical Trials Office, Chief, Section of GI Medical Oncology, University of Arizona Cancer Center, elaborates on ...

video

Rachna Shroff, MD, on the most promising pathways for targeted therapies in GI cancers

Dr. Shroff, Medical Director, Clinical Trials Office, Chief, Section of GI Medical Oncology, University of Arizona Cancer Center, discusses the ...

video

Ken Kato, MD, PhD, on the role of PD-L1 biomarkers in the treatment of esophageal cancer

Dr. Kato, Specialist, Clinical Oncology, National Cancer Center Hospital, Tokyo, Japan, discusses the role of PD-L1 biomarkers in determining treatment ...

video

Ken Kato, MD, PhD, regarding the treatment of adenocarcinoma versus squamous cell carcinoma

Dr. Kato, Specialist, Clinical Oncology, National Cancer Center Hospital, Tokyo, Japan, considers key takeaways from the Keynote-590 clinical trial regarding ...

video

Ken Kato, MD, PhD, shares the design and outcomes of the Keynote-590 trial from ESMO 2020

Dr. Kato, Specialist, Clinical Oncology, National Cancer Center Hospital, Tokyo, Japan, shares the design and outcomes of the Keynote-590 trial ...

video

Geoffrey Y. Ku, MD, on treating squamous cell carcinoma versus adenocarcinoma of the esophagus

Dr. Ku, Medical Oncologist, Memorial Sloan Kettering Cancer Center, considers how squamous cell carcinoma versus adenocarcinoma of the esophagus should ...

video

Jaffer Ajani, MD, elaborates on the role of PD-L1 biomarkers in determining treatment decisions

Dr. Ajani, Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer ...

video

Geoffrey Y. Ku, MD, provides perspective on the CheckMate-577 clinical study presented at ESMO 2020

Dr. Ku, Medical Oncologist, Memorial Sloan Kettering Cancer Center, provides perspective on the CheckMate-577 clinical study investigating the use of ...

video

Jaffer Ajani, MD, considers results from the CheckMate 649 study presented at ESMO 2020

Dr. Ajani, Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer ...

video

Jaffer Ajani, MD, shares thoughts on the CheckMate 577 study presented at ESMO 2020

Dr. Ajani, Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer ...

Related Videos

video-image

Eleni Efstathiou, MD, PhD, regarding the preliminary analysis of belzutifan & cabozantinib in ccRCC

video-image

Jorge A. Garcia, MD, summarizes the significance of CheckMate 9ER from ASCO GU 2021

video-image

Sumanta K. Pal, MD, offers a message to patients regarding clinical progress in kidney cancer

video-image

Sumanta K. Pal, MD, shares thoughts on the TIVO-3 trial from ASCO GU 2021

video-image

Sumanta K. Pal, MD, offers opinion on the treatment of clear cell renal cell carcinoma

video-image

Sumanta K. Pal, MD, elaborates on the significance of the CLEAR trial from ASCO GU 2021

video-image

Sumanta K. Pal, MD, regarding the quality of life outcomes from CheckMate 9ER

video-image

Sumanta K. Pal, MD, considers the unmet needs in the treatment of papillary RCC

video-image

Sumanta K. Pal, MD, elaborates on the design and outcomes of the PAPMET trial from ASCO GU 2021

video-image

Robert J. Motzer, MD, elaborates on key findings from the Phase III CLEAR trial

video-image

Robert J. Motzer, MD, offers opinion on whether findings from the CLEAR trial are practice-changing

video-image

Robert J. Motzer, MD, discusses the side effect profiles of the combinations in the CLEAR trial

video-image

Robert J. Motzer, MD, speculates on the future role of combination therapy in advanced ccRCC

video-image

Robert J. Motzer, MD, considers the issue of drug resistance in treating advanced ccRCC

video-image

David A. Braun, MD, PhD, regarding the follow-up trial investigating MK-6482 in ccRCC

video-image

David A. Braun, MD, PhD, discusses the preliminary analysis of belzutifan + cabozantinib in ccRCC

video-image

Jeanny B. Aragon-Ching, MD, FACP, regarding the CheckMate-9ER trial presented at GU 2021

video-image

David Braun, MD, PhD, shares how the treatment of ccRCC in the refractory setting is changing

video-image

David Braun, MD, PhD, considers the evolving treatment landscape of 1st line ccRCC

video-image

David Braun, MD, PhD, offers opinion on the role of HIF-2α inhibitors in ccRCC

video-image

Rachna Shroff, MD, elaborates on newly approved targeted therapies in esophagogastric cancer

video-image

Rachna Shroff, MD, on the most promising pathways for targeted therapies in GI cancers

video-image

Eleni Efstathiou, MD, PhD, regarding patients more likely to respond to nivolumab + cabozantinib

video-image

Eleni Efstathiou, MD, PhD, offers opinion on whether CheckMate 9ER is practice-changing

video-image

Eleni Efstathiou, MD, PhD, discusses the CheckMate 9ER clinical trial presented at ESMO 2020

video-image

Ken Kato, MD, PhD, on the role of PD-L1 biomarkers in the treatment of esophageal cancer

video-image

Ken Kato, MD, PhD, regarding the treatment of adenocarcinoma versus squamous cell carcinoma

video-image

Ken Kato, MD, PhD, shares the design and outcomes of the Keynote-590 trial from ESMO 2020

video-image

Jaffer Ajani, MD, elaborates on the role of PD-L1 biomarkers in determining treatment decisions

video-image

Geoffrey Y. Ku, MD, provides perspective on the CheckMate-577 clinical study presented at ESMO 2020

video-image

Geoffrey Y. Ku, MD, on treating squamous cell carcinoma versus adenocarcinoma of the esophagus

video-image

Laurence Albigès, MD, PhD, on patient responses to combo nivolumab + ipilimumab in 1st line RCC

video-image

Jaffer Ajani, MD, considers results from the CheckMate 649 study presented at ESMO 2020

video-image

Jaffer Ajani, MD, shares thoughts on the CheckMate 577 study presented at ESMO 2020

video-image

Laurence Albigès, MD, PhD, offers opinion on whether CheckMate 214 is practice-changing

video-image

Laurence Albigès, MD, PhD, shares outcomes & updates from the CheckMate 214 study in advanced RCC

video-image

Cristina Suárez, MD, on patient subtype responses to combo nivolumab + cabozantinib in 1st line RCC

video-image

Cristina Suárez, MD, offers opinion on whether the CheckMate 9ER trial is practice-changing

video-image

Cristina Suárez, MD, compares the control arm of CheckMate 9ER with current 1st line RCC regimens

video-image

Cristina Suárez, MD, elaborates on the outcomes of the CheckMate 9ER study presented at ESMO 2020

video-image

Cristina Suárez, MD, on the promise of I-O in advanced renal cell carcinoma

video-image

Sumanta Kumar Pal, MD, regarding HIF-2 being the next target for novel precision cancer medicine

video-image

Sumanta Kumar Pal, MD, discusses the strategy of combining and/or sequencing Immunotherapy and TKIs in advanced RCC management

video-image

Sumanta Kumar Pal, MD, discusses his recently published work and how it has impacted approach to RCC

video-image

Sumanta Kumar Pal, MD, shares current treatment approach for a patient with advanced renal cell cancer

video-image

Rana McKay, MD, discusses factors considered when deciding which patients to get an I-O combo in RCC

video-image

Rana McKay, MD, discusses the unmet needs for clinical trials addressing non-clear cell RCC

video-image

Rana McKay, MD, explains approach to treating 2nd-line RCC patients who have received I-O combination

video-image

Rana McKay, MD, discusses the design and outcomes of the Phase 3 randomized Keynote 426 study in 1st line clear cell renal cell cancer (RCC)

video-image

Toni Choueiri, MD, describes potential importance of combining ipi/nivo for 1st line renal cell carcinoma patients

video-image

Toni Choueiri, MD, describes treatment strategies for 2nd line renal cell carcinoma

video-image

Derek Raghavan, MD, on the role of nephrectomy in the age of targeted therapies and immunotherapy

video-image

Toni Choueiri, MD, provides observations into the dynamic field of kidney cancer

video-image

Toni Choueiri, MD, considers the next steps in the further development of HIF-2 inhibitors

video-image

Toni Choueiri, MD, makes predictions for triplet combinations in the treatment of RCC

video-image

Toni Choueiri, MD, discusses approach to first line treatment of clear cell renal cell cancers

video-image

Toni Choueiri, MD, provides updates on HIF-2 alpha inhibitors in renal call cancer

video-image

Elizabeth Plimack, MD, on differentiating 1st line RCC patients when selecting a combination regimen

video-image

Elizabeth Plimack, MD, on treating 2nd line RCC patients that have received an I-0 combination in the 1st line setting

video-image

Eric Jonasch, MD, discusses the incidence of Von Hippel-Lindau Disease among RCC patients

video-image

Eric Jonasch, MD, expounds on the use of MK-6482 in both RCC and non-RCC tumors

video-image

Eric Jonasch, MD, explains the development process for MK-6482 and hopes for future studies

video-image

Eric Jonasch, MD, on the 4 year Checkmate-214 follow up investigating nivolumab + ipilimumab

video-image

Eric Jonasch, MD, considers the combination and/or sequencing IO and TKIs in advanced RCC management

video-image

Eric Jonasch, MD, recognizes interesting clinical presentations regarding RCC management at ASCO20

video-image

Elizabeth Plimack, MD, explains the design and outcomes of the Phase 3 randomized Keynote 426 study

video-image

Eric Jonasch, MD, explains MK-6482 and the tumor types it will be most effective in

video-image

Bradley McGregor, MD, discusses Checkmate-214 investigating nivolumab + ipilimumab in 1st line renal cell carcinoma patients

video-image

David Quinn, MD, on best utilization of stereotactic radiation in the management of advanced renal cell carcinoma patients

video-image

David Quinn, MD, discusses Checkmate-214 investigating nivolumab + ipilimumab in advanced renal cell carcinoma patients

video-image

David Quinn, MD, describes if biomarkers help guide treatment in advanced renal cell carcinoma

video-image

Tian Zhang, MD, on follow up investigation of Checkmate 025 in renal cell carcinoma patients

video-image

Michael Atkins, MD, shares exciting potential of current late-stage clinical studies in renal cell cancer patients

video-image

Michael Atkins, MD, on metastatic renal cancer patients whose cancer returns and were previously treated with I-O

video-image

Michael Atkins, MD, on appropriate patient types to receive a TKI in the treatment of 1st line RCC patients

video-image

Michael Atkins, MD, discusses the 4 year follow up of Checkmate-214 investigating nivolumab + ipilimumab in 1st line renal cell carcinoma patients

video-image

Robert Figlin, MD, shares exciting potential of current late-stage clinical studies in RCC patients

video-image

Robert Figlin, MD, on appropriate patient types to receive a TKI in the treatment of 1st line renal cell carcinoma patients

video-image

Rana McKay, MD, shares exciting potential of current late-stage clinical studies in RCC patients

video-image

Rana McKay, MD, discusses mRCC patients whose cancer returns and were previously treated with I-O

video-image

Rana McKay, MD, deliberates on patient types appropriate to receive a TKI in the treatment of RCC

video-image

Nizar Tannir, MD, shares strategy of IO and TKIs when managing treatment of advanced RCC patients.

video-image

Tian Zhang, MD, on the follow up study investigating nivolumab + ipilimumab in 1st line RCC patients

video-image

Nizar Tannir, MD, describes the 4 year follow up study of nivolumab + ipilimumab in RCC patients

video-image

David Quinn, MD, on impressions of phase I/II study of oral HIF-2 α inhibitor MK-6482 in patients with advanced clear renal cell carcinoma

video-image

Michael Atkins, MD, on follow up investigation of Checkmate 025 in renal cell carcinoma patients

video-image

Bradley McGregor, MD, describes whether biomarkers help guide treatment in advanced renal cell carcinoma

video-image

Bradley McGregor, MD, on impressions of phase I/II study of oral HIF-2 α inhibitor MK-6482 in patients with advanced clear renal cell carcinoma

video-image

Tian Zhang, MD, elaborates on the PEDIGREE clinical study in advanced renal cell cancer patients

video-image

Robert Figlin, MD, on treatment of returning metastatic renal cancer when previously treated with I-O

video-image

Rana McKay, MD discusses Checkmate 214 investigating nivolumab + ipilimumab in 1st line RCC patients

video-image

Manish Shah, MD, on the role of Cyramza in the treatment of gastric and esophageal cancers

video-image

Daniel Catenacci, MD, discusses margetuximab in the treatment of esophageal and gastric cancer

video-image

Daniel Catenacci, MD, elaborates on the outcomes of the JAVELIN 100 study presented at ASCO GI 2020

video-image

Che-Kai Tsao, MD, discusses the current application of biomarkers in renal cell carcinoma

video-image

Che-Kai Tsao, MD, on deciding between I-O + TKIs combinations indicated for the treatment of RCC

video-image

Robert A. Figlin, MD, speculates on clinical advances in renal cell carcinoma

video-image

Nancy A. Dawson, MD, regarding preferred agents in the 2nd line setting in renal cell carcinoma

video-image

Robert A. Figlin, MD, regarding the role of systemic therapy in oligometastatic RCC

video-image

Nancy A. Dawson, MD, on selecting the appropriate I-O + TKI combo in the treatment of 1st line RCC

video-image

Michael B. Atkins, MD, comments on clinical trials investigating the use of I-O and TKIs in RCC

video-image

Che-Kai Tsao, MD, considers the various I-O and TKI combinations available for 1st line RCC

video-image

Robert A. Figlin, MD, on I-O & TKIs available and indicated for the treatment of 2nd line RCC

video-image

Michael B. Atkins, MD, considers preferred agents in the treatment of RCC in the 2nd line

video-image

Che-Kai Tsao, MD, regarding the evolving landscape of metastatic clear cell RCC

video-image

Robert A. Figlin, MD, considers combination I-O and TKIs indicated for the treatment of 1st line RCC

video-image

Michael B. Atkins, MD, on selecting I-O and TKI combinations for the treatment of 1st line RCC

video-image

Bradley McGregor, MD, considers strategies for treating 2nd line RCC patients

video-image

Tian Zhang, MD, discusses the most anticipated trial results regarding biomarkers in RCC

video-image

Tian Zhang, MD, regarding strategies for treating RCC in the 2nd line setting

video-image

Tian Zhang, MD, offers perspective on treating newly diagnosed RCC patients

video-image

Bradley McGregor, MD, considers the optimal approach to treating newly diagnosed RCC patients

video-image

Tian Zhang, MD, on promising studies in sarcomatoid RCC & urothelial cancer from ASCO '19

video-image

Tian Zhang, MD, shares thoughts on the PDIGREE trial in metastatic, untreated RCC

video-image

Tian Zhang, MD, explains how to treat mRCC after combination I-O in the 1st line setting

video-image

Michael Atkins, MD, considers how to treat mRCC after combination I-O in the 1st line setting

video-image

Tian Zhang, MD, discusses intermediate/poor and favorable risk RCC patients

video-image

Michael Atkins, MD, considers intermediate/poor & favorable risk RCC patients

video-image

Tian Zhang, MD, elaborates on the outcomes of KEYNOTE 426 presented at GU 2019

video-image

Tian Zhang, MD, on predictive biomarkers in selecting patient populations for I-O treatment in RCC

video-image

Rana McKay, MD, explains how to differentiate between TKIs available for renal cell cancer patients

video-image

Rana McKay, MD, on next steps when treating mRCC patients who receive I-O in the front line space

video-image

Rana McKay, MD, offers impressions of the TIVO-3 study in highly refractory advanced RCC patients

video-image

Rana McKay, MD, on recent data examining atezolizumab and bevacizumab in nccRCC & sccRCC

video-image

Rana McKay, MD, considers the implications of CHECKMATE 214 & KEYNOTE-426 presented at GU 2019

video-image

Rana McKay, MD, elaborates on the outcomes of the KEYNOTE 426 Phase III study in mRCC

video-image

Michael Atkins, MD, offers opinion on IO-TKI combinations in renal cell cancer

video-image

Michael Atkins, MD, regarding the KEYNOTE 426 Phase III trial in metastatic renal cell carcinoma

video-image

David Ilson, MD, PhD, on the use of biomarkers in the treatment of esophagogastric cancer

video-image

David Ilson, MD, PhD, summarizes the role of I-O in esophagogastric cancer treatment algorithms

video-image

John Strickler, MD, regarding pembrolizumab vs. chemotherapy in 2nd line advanced esophageal cancer

video-image

John Strickler, MD, on combo pembrolizumab, trastuzumab, capecitabine & oxaliplatin in mEGA

video-image

David Ilson, MD, PhD, on pembrolizumab, trastuzumab, capecitabine & oxaliplatin in HER2+ mEGA

video-image

Raymond Wadlow, MD, on the outcomes of Keynote 181 in esophageal cancer

video-image

David Ilson, MD, PhD, compares pembrolizumab & chemotherapy in advanced esophageal cancer

video-image

Robert A. Figlin, MD, on the convenience factor of oral TKIs & treatment decisions in advanced RCC

video-image

Robert A. Figlin, MD, on the trade-offs between safety & efficacy when discussing 1st line RCC

video-image

Robert A. Figlin, MD, provides perspective on I-O failures

video-image

Robert A. Figlin, MD, on deciding which metastatic RCC patients should get a TKI as 1st line therapy

video-image

Robert A. Figlin, MD, on how checkpoint inhibitors figure into treatment for 1st line RCC patients

video-image

Walter Stadler, MD, regarding TKIs in the treatment of renal cell carcinoma

video-image

Walter Stadler, MD, on treating RCC in the 2nd line setting following I-O failure

video-image

Walter Stadler, MD, considers which mRCC patients should receive a TKI as 1st line therapy

video-image

David I. Quinn, MD, provides perspective on the trade-offs between safety & efficacy in 1st line RCC

video-image

David I. Quinn, MD, considers whether the convenience of oral TKIs impacts RCC treatment

video-image

David I. Quinn, MD, comments on 2nd line therapy options following I-O failure

video-image

David I. Quinn, MD, shares thoughts on Keynote 427 from the 2018 ASCO Annual Meeting

video-image

David I. Quinn, MD, regarding the most exciting RCC data coming out of ASCO 2018

video-image

Jeanny B. Aragon-Ching, MD, FACP, shares how checkpoint inhibitors fit into RCC treatment algorithms

video-image

Jeanny B. Aragon-Ching, MD, FACP, comments on 2nd line treatment options in RCC after I-O failure

video-image

Primo N. Lara, Jr., MD, comments on which TKIs appear most effective in 1st line RCC

video-image

Primo N. Lara, Jr., MD, on whether the convenience of oral TKIs influences treatment decisions

video-image

Primo N. Lara, Jr., MD, considers the trade-offs between safety & efficacy in 1st line RCC treatment

video-image

Primo N. Lara, Jr., MD, regarding the treatment path following I-O failure

video-image

Primo N. Lara, Jr., MD, on deciding which mRCC patients should receive a TKI

video-image

Primo N. Lara, Jr., MD, on how checkpoint inhibitors fit into RCC treatment algorithms

video-image

Brian I. Rini, MD, FACP, comments on the CARMENA study presented at ASCO 2018

video-image

Brian I. Rini, MD, FACP, discusses the influence of the convenience of oral TKIs

video-image

Brian I. Rini, MD, FACP, regarding the trade-offs between safety & efficacy in 1st line RCC

video-image

Brian I. Rini, MD, FACP, considers 2nd line treatment in advanced RCC following I-O failure

video-image

Brian I. Rini, MD, FACP, on which metastatic RCC patients should receive a TKI as 1st line therapy

video-image

Brian I. Rini, MD, FACP, on how checkpoint inhibitors figure into treatment algorithms for RCC

video-image

David I. Quinn, MD, on which metastatic RCC patients should receive a TKI as first-line therapy

video-image

Naomi B. Haas, MD, on how patient characteristics play a role in sequencing in metastatic RCC

video-image

Naomi B. Haas, MD, on how immunotherapies are being integrated into kidney cancer treatment

video-image

Naomi B. Haas, MD, explains how cabozantinib is being integrated into treatment of renal cell cancer

video-image

Naomi B. Haas, MD, offers opinion on the optimal sequencing of agents in treatment of RCC

video-image

Naomi B. Haas, MD, considers the role of TKIs in the treatment of renal cell cancer

video-image

Naomi B. Haas, MD, on what clinical evidence can tell us about the adjuvant treatment of RCC

video-image

Daniel J. George, MD, regarding toxicity concerns when using sunitinib in RCC

video-image

Daniel J. George, MD, on the effectiveness of sunitinib in the adjuvant treatment of high-risk RCC

video-image

David Ilson, MD, PhD, discusses what can be done to improve outcomes in esophageal adenocarcinoma

video-image

Khaldoun Almhanna, MD, MPH, discusses the risk factors to watch for gastroesophageal cancer

video-image

Kenneth Wang, MD, offers opinion on approaches to treating esophageal cancer

video-image

Kenneth Wang, MD, on managing esophageal cancer patients who have completed neoadjuvant therapy

video-image

Kenneth Wang, MD, on how to assess response in esophageal cancer and utilize the information

video-image

Khaldoun Almhanna, MD, MPH, on surveillance and the management of gastroesophageal cancer

video-image

Kenneth Wang, MD, considers how staging esophageal cancer has changed and improved

video-image

Jeffrey Meyerhardt, MD, on how immunotherapies are being studied in gastric & esophageal cancers

video-image

Robert Figlin, MD, explains how checkpoint inhibitors are changing the way RCC is treated

video-image

Robert Figlin, MD, discusses sequencing when treating metastatic RCC patients

video-image

Robert Figlin, MD, on choosing the most appropriate treatment algorithm for metastatic RCC patients

video-image

Robert Figlin, MD, offers his opinion on interesting abstracts at ASCO 2017 related to RCC

video-image

Robert Figlin, MD, speculates on the changing landscape of RCC treatment

video-image

Ulka N. Vaishampayan, MD, on challenges facing patients and providers

video-image

Mohamad E. Allaf, MD, on immunotherapies and renal cell carcinoma treatment algorithms

video-image

Eric Jonasch, MD, on integrating immunotherapies into renal cell carcinoma treatment algorithms

video-image

Mohamad E. Allaf, MD, provides insight into treating metastatic non-clear cell renal cell carcinoma

video-image

Ulka N. Vaishampayan, MD, on immunotherapies and renal cell carcinoma treatment algorithms

video-image

Eric Jonasch, MD, on targeted therapies used to treat non-clear cell renal cell carcinoma

video-image

Eric Jonasch, MD, on approaches to consider with metastatic non-clear renal cell carcinoma

video-image

Aly-Khan Lalani, MD, offers feedback on using immunotherapies to treat renal cell carcinoma patients

video-image

Mohamad E. Allaf, MD, on helping non-metastatic renal cell carcinoma patients with adjuvant therapy

video-image

Ulka N. Vaishampayan, MD, on metastatic renal cell carcinoma patients and chemotherapy

video-image

Eric Jonasch, MD, on treating non-metastatic renal cell carcinoma patients with adjuvant therapy

video-image

Aly-Khan Lalani, MD, examines the integration of immunotherapies for renal cell carcinoma treatment

video-image

Mohamad E. Allaf, MD, on non-metastatic renal cell cancer patients and adjuvant therapy

video-image

Eric Jonasch, MD, on which non-metastatic renal cell cancer patients should receive adjuvant therapy

video-image

Robert A. Figlin, MD on clinical study that lead to approval of lenvatinib (Lenvima)

video-image

Robert Figlin, MD discusses how lenvatanib will fit into the advanced RCC treatment algorithm

video-image

Robert Figlin, MD, discusses recent progress in the treatment of renal cell cancer (RCC)

video-image

Robert Filgin MD explains the importance of cabozantinib as a tool in the RCC armamentarium

video-image

Robert Filgin MD provides an update on nivolumab (Opdivo) in RCC

video-image

Kidney Cancer Highlights from ASCO GU 2016 Genitourinary Symposium

video-image

Using anti-angiogenic agents in advanced gastric and esophagogastric adenocarcinomas ASCO GI 2016

video-image

Post-operative adjuvant therapy for resectable patients with node positive oesophageal cancer ASCO GI 2016

video-image

Geoffrey Ku, MD, summarizes the FIGHT clinical trial as presented at ASCO GI 2021

video-image

Geoffrey Ku, MD, considers the mechanism of action and future development of zanidatamab

video-image

Geoffrey Ku, MD, regarding the use of trastuzumab deruxtecan in gastric or GE junction cancer

video-image

Tanios Bekaii-Saab, MD, FACP, offers opinion on the updated KEYNOTE-177 as presented at ASCO GI 2021

video-image

Tanios Bekaii-Saab, MD, FACP, summarizes data regarding circulating tumor cells from ASCO GI 2021

video-image

Richard S. Finn, MD, regarding the updated IMbrave150 data from ASCO GI 2021

video-image

Richard S. Finn, MD, tells us about the safety profile of atezolizumab & bevacizumab from IMbrave150

video-image

Richard S. Finn, MD, considers whether updated results from IMbrave150 are practice-changing

video-image

Richard S. Finn, MD, offers opinion on the role of frontline atezolizumab + bevacizumab in HCC

video-image

Richard S. Finn, MD, elaborates on promising developments in the second-line treatment of HCC

video-image

Namrata Vijayvergia, MD, discusses updates from the IMbrave150 trial as presented at ASCO GI 2021

video-image

Namrata Vijayvergia, MD, considers updated data from the CheckMate 040 trial in advanced HCC

video-image

Namrata Vijayvergia, MD, offers opinion on the use of FGFR inhibitors in the treatment of CCA

video-image

Andrew X. Zhu, MD, PhD, discusses the final results of the ClarIDHy trial from ASCO GI 2021

video-image

Andrew X. Zhu, MD, PhD, speculates on the potential impact of the ClarIDHy trial

video-image

Andrew X. Zhu, MD, PhD, elaborates on the role of genetic testing in cholangiocarcinoma

video-image

Andrew X. Zhu, MD, PhD, on ivosidenib as a 1st line therapy for patients with CCA & an IDH1 mutation

video-image

Thomas J. George, MD, regarding the NRG-GI002 trial as presented at ASCO GI 2021

video-image

Zev Wainberg, MD, elaborates on outcomes from the FIGHT trial as presented at ASCO GI 2021

video-image

Thomas J. George, MD, elaborates on the design of the NRG-GI002 clinical trial

video-image

Zev Wainberg, MD, discusses the safety profile of bemarituzumab

video-image

Thomas J. George, MD, considers results from the experimental arms of the NRG-GI002 clinical trial

video-image

Zev Wainberg, MD, speculates on the role of bemarituzumab in other FGFR2b-positive tumor types

video-image

Thomas J. George, MD, discusses the side effect profile of pembrolizumab in the NRG-GI002 trial

video-image

Zev Wainberg, MD, considers the influence of ctDNA testing in the treatment of gastric cancer

video-image

Thomas J. George, MD, on the evolving treatment landscape of locally advanced rectal cancer

video-image

Rachna Shroff, MD, tells us about the NuTide:121 trial as presented at GI 2021

video-image

Rachna Shroff, MD, shares perspective on newly approved targeted therapies in hepatobiliary cancer

video-image

Rachna Shroff, MD, considers the progress of targeted therapies in GI cancer

video-image

Geoffrey Y. Ku, MD, offers opinion on the practice-changing potential of the CheckMate-649 study

video-image

Jaffer Ajani, MD, provides opinion on the role of I-O in treatment of esophageal & gastric cancers

video-image

Zarnie Lwin, MBBS, FRACP, shares the design & outcomes of the LEAP-005 Phase II study from ESMO 2020

video-image

Howard Hochster, MD, explains the role of ramucirumab in the treatment of GE junction cancers

video-image

Alan Venook, MD, provides thoughts on the clinical progress of trastuzumab-deruxtecan in GI cancers

video-image

Tom Beer, MD, describes use of DNA repair markers when determining treatment of prostate cancer

video-image

Tilak Sundaresan, MD, regarding the results of the TAPUR study and its importance to physicians

video-image

Tilak Sundaresan, MD, determines whether to automatically test for the BRAF mutation in patients

video-image

Tilak Sundaresan, MD, shares how "sided-ness" affects the use of EGFR inhibitors in CRC treatment

video-image

Tilak Sundaresan, MD, discusses combining regorafenib and checkpoint inhibitors in advanced CRC

video-image

Tilak Sundaresan, MD, elaborates on the influence of cell free DNA when managing CRC patients

video-image

Crystal Denlinger, MD, offers opinion on checkpoint inhibitors being used in anal cancer management

video-image

Crystal Denlinger, MD, discusses quality of life analysis in the IMBRAVE study presented at ASCO GI

video-image

Crystal Denlinger, MD, regarding cell free DNA tests and their influence on the treatment of CRC patients

video-image

Crystal Denlinger, MD, comments on the use of fitness trackers in regards to management of CRC

video-image

David H Ilson, MD, elaborates on updated data from the BEACON study presented at ASCO GI 2020

video-image

David H Ilson, MD, on the JAVELIN 100 study and the need for quick responses and immunotherapy in GE

video-image

Zev Wainberg, MD, on the role of pembrolizumab for MSI high CRC patients and its use in therapy

video-image

Zev Wainberg, MD, explains appropriate therapy following initial treatment for GI & GE tumors

video-image

Zev Wainberg, MD, shares the best way to combine checkpoint inhibitors in gastric and GE tumors

video-image

Zev Wainberg, MD, on the line of therapy for checkpoint inhibitors in gastric and GI cancers

video-image

Hani Babiker, MD, on tumor treatment field combinations in the management of GI malignancies

video-image

Hani Babiker, MD, defines tumor treatment fields as well as the mechanism of action

video-image

Ahmed Kaseb, MD, on the differentiation of levatinib vs cabozantinib for HCC treatment

video-image

Ahmed Kaseb, MD, explains the role of immunotherapy in neo-adjuvant treatment of resectable HCC

video-image

Ahmed Kaseb, MD, shares the role of checkpoint inhibitors when alone and combined with anti-CTLA4

video-image

Irvin Modlin, MD, explains the reason NETest is more effective than a biomarker test such as CGA

video-image

Irvin Modlin, MD, describes whether NETest replaces or supplements imaging

video-image

Irvin Modlin, MD, offers opinion of NETest and whether it is cost prohibitive

video-image

Irvin Modlin, MD, explains the specificity and sensitivity of the NETest

video-image

Irvin Modlin, MD, shares importance of NETest, requirement for testing, and where to send results

video-image

Nevena Damjanov, MD, shares personal opinion of treatment of patient with a high expression of AFP

video-image

Eileen O'Reilly, MD, shares outcomes of the POLO study and its importance to physicians

video-image

Eileen O'Reilly, MD, describes how physicians should test for BRCA in pancreatic cancer patients

video-image

Sam Klempner, MD, describes the role of Cyramza in the treatment of GR junction cancers

video-image

Sam Klempner, MD, considers promising approaches to therapy in development for upper GI malignancies

video-image

Manish Shah, MD, discusses avelumab's effectiveness based on results from the JAVELIN 100 study

video-image

Manish Shah, MD, explains whether levatinib can be combined with I-O to treat and manage GI cancer

video-image

Manish Shah, MD, describes BRAF testing tactics and how it affects treatment of CRC patients

video-image

Irvin Modlin, MD, on when to use NETest clinically and situations it has clinical utility

video-image

Daniel Catenacci, MD, on the role of margetuximab to improve treatment outcomes of GI cancers

video-image

Daniel Catenacci, MD, shares opinion on the role of checkpoint inhibitors for GI malignancies

video-image

Philip Philip, MD, on the phase 2 study comparing chemo with or without veliparib in pancreas

video-image

Philip Philip, MD, shares opinion on treatment of a BRCA+ pancreatic cancer patient

video-image

Philip Philip, MD, explains how physicians should test for BRCA in pancreatic cancer patients

video-image

Philip Philip, MD, on the outcomes of the POLO study and its importance to physicians

video-image

Daneng Li, MD, regarding the role of immunotherapy in the neoadjuvant and adjuvant setting for HCC

video-image

Daneng Li, MD, shares latest thoughts on checkpoint inhibitors being combines with TKIs

video-image

Ryan Corcoran, MD, on the current use of MRD as a valid test for determining GI cancer treatment

video-image

Ryan Corcoran, MD, explains the need for the MRD test in CRC and whether its ready for prime time

video-image

Ryan Corcoran, explains cell free DNA and ways to test for it

video-image

Richard Kim, MD, on results of phase 1 study regarding locally advanced rectal adenocarcioma

video-image

Richard Kim, MD, explains how "sided-ness" affects usage of EGFR inhibitors in the treatment of CRC

video-image

Richard Kim, MD, on the combination of cabozantinib and checkpoint inhibitors to improve HCC outcomes

video-image

Benjamin Weinberg, comments on the use of intratumoral microbiome assessment vs GI tract assessment

video-image

Benjamin Weinberg, MD, on the microbiome and the development of colorectal malignancies

video-image

Benjamin Weinberg, MD, on demographic results associated with the microbiome and CRC

video-image

Philip Philip, MD, provides thoughts on the role of PARP inhibitors in advanced pancreatic cancer

video-image

Crystal Denlinger, MD, explains differentiation of treatment of CRC patients based on age

video-image

Crystal Denlinger, MD, shares data regarding first line biliary tract cancer patients

video-image

David H Ilson, MD, shares perspective of the IPACS study regarding stage 4 CRC patients

video-image

David H Ilson, MD, shares results of the ARTDECO study and it's importance to physicians

video-image

Zev Wainberg, MD, shares results of study regarding gastric and GE cancers presented at ASCO GI

video-image

Ryan Corcoran, MD, elaborates on promising clinical applications of cell free DNA

video-image

Richard Kim, MD, on the outcome on the IMBRAVE 150 study & the possibility of new treatment standard

video-image

Daneng Li, MD, on combining cabozantinib with checkpoint inhibitors to improve patient outcomes

video-image

Richard Kim, MD determines whether checkpoint inhibitors combine with regorafenib for HCC treatment

video-image

Daneng Li, MD, on impressions of patient reported outcomes from the IMBRAVE 150 study

video-image

Hani Babiker, MD, elaborates on tumor treatment fields applying to GI malignancies

video-image

Hani Babiker, MD, describes the setting of FDA approval on tumor treatment fields

video-image

Ahmed Kaseb, MD, on combining cabozantinib with checkpoint inhibitors for treatment of HCC

video-image

Ahmed Kaseb, MD, on survival outcomes in the IMBRAVE 150 phase 3 study

video-image

Nevena Damjanov, MD, on impressions of the study combining cabozantinib with checkpoint inhibitors in advanced HCC patients

video-image

Nevena Damjanov, MD, elaborates on the role of TKIs in managing 2nd line HCC patients

video-image

Nevena Damjanov, MD, explains the outcomes of combining atezolizumab with bevacizumab in 1st line HCC patients

video-image

Eileen O'Reilly, MD, on the phase 2 study comparing chemo with or without veliparib in pancreas

video-image

Eileen O'Reilly, MD, provides evidence to inform treatment of pancreatic cancer patients

video-image

Sam Klempner, MD, explains how circulating tumor DNA can be used to help determine therapy

video-image

Manish Shah, MD, regarding the use of liquid biopsy to diagnose and treat GI cancers

video-image

Josep Tabernero, MD, PhD, speculates on exciting clinical trial outcomes in gastric cancer

video-image

Josep Tabernero, MD, PhD, offers perspective on Keynote-062 in advanced gastroesophageal

video-image

Thomas A. Abrams, MD, offers thoughts on Keynote-062 in gastric/gastroesophageal cancer

video-image

Richard Finn, MD, outlines the role of TACE with systemic therapy in HCC

video-image

Richard Finn, MD, considers the effectiveness of sorafenib + I-O in newly diagnosed HCC

video-image

John Strickler, MD, shares thoughts on molecular subtyping of pancreatic cancer

video-image

John Strickler, MD, on how next-generation sequencing fits into treatment of mCRC

video-image

Raymond Wadlow, MD, on surrogate biomarkers in the treatment of hepatocellular carcinoma

video-image

Richard Finn, MD, elaborates on current treatment options & sequencing of TKIs in HCC

video-image

Zev Wainberg, MD, regarding the results of the ROAR basket trial from GI 2019

video-image

Raymond Wadlow, MD, speculates on the use of TKIs in the management of HCC

video-image

Zev Wainberg, MD, considers regorafenib in locally advanced biliary tract cancer

video-image

Raymond Wadlow, MD, regarding BSC vs. combination checkpoint inhibitors in advanced CRC

video-image

Zev Wainberg, MD, on checkpoint inhibition with chemotherapy in pancreatic cancer

video-image

Bassel El-Reyes, MD, speculates on promising novel therapies being developed for pancreatic cancer

video-image

Bassel El-Reyes, MD, considers upfront surgery for resectable pancreatic cancer

video-image

Martine Extermann, MD, PhD, on identifying the right treatment for patients with gastric cancer

video-image

Bassel El-Reyes, MD, offers his opinion on NGS & BRCA gene testing for pancreatic cancer

video-image

Martine Extermann, MD, PhD, shares the results of the FOLFOX +/- andecaliximab study from GI '19

video-image

Bassel El-Reyes, MD, regarding molecular subtyping of pancreatic cancer

video-image

Martine Extermann, MD, PhD, on the investigation of TAS-102 in metastatic gastric cancer

video-image

Bassel El-Reyes, MD, on screening patients at high risk for pancreatic cancer

video-image

Richard Finn, MD, speculates on combined checkpoint inhibition in HCC & biliary tract cancer

video-image

Richard Finn, MD, shares his thoughts on the role of systemic therapy in HCC

video-image

David Ilson, MD, PhD, shares results from the TAGS trial presented at GI 2019

video-image

Rachna Shroff, MD, gives her take on pre-operative therapy in resectable pancreatic cancer

video-image

Richard Kim, MD, regarding the use of regorafenib in treatment of colorectal cancer

video-image

Rachna Shroff, MD, on the utilization of TKIs in treatment of hepatocellular carcinoma

video-image

Richard Kim, MD, shares how we can utilize TKIs in the management of hepatocellular carcinoma

video-image

Rachna Shroff, MD, discusses how BRAF mutations figure into cholangiocarcinoma treatment

video-image

Rachna Shroff, MD, expands on targeted therapies in the treatment of cholangiocarcinoma

video-image

Richard Kim, MD, on the role of BRAF mutations in treatment of cholangiocarcinoma

video-image

Richard Kim, MD, regarding targeted therapies in treatment of cholangiocarcinoma

video-image

Andrew X. Zhu, MD, PhD, considers whether sorafenib is tolerable in combination with I-O in HCC

video-image

Andrew X. Zhu, MD, PhD, on what physicians should know about sequencing TKIs in HCC

video-image

Andrew X. Zhu, MD, PhD, regarding checkpoint inhibitors in advanced HCC

video-image

Axel Grothey, MD, on the CCTG CO.26 trial in advanced refractory CRC presented at GI 2019

video-image

Alan Venook, MD, shares key takeaways from GI 2019 regarding the treatment of biliary tract cancers

video-image

Axel Grothey, MD, on the use of regorafenib in the management of advanced CRC

video-image

Alan Venook, MD, on the latest in identifying valid biomarkers in the treatment of HCC

video-image

Axel Grothey, MD, on patient selection & treatment algorithms in 2nd and 3rd line CRC

video-image

Alan Venook, MD, tells us whether ctDNA is a valid treatment response in CRC

video-image

Axel Grothey, MD, considers the role of circulating tumor DNA (ctDNA)

video-image

Alan Venook, MD, discusses next generation sequencing and mCRC treatment

video-image

Axel Grothey, MD, elaborates on next generation sequencing and mCRC

video-image

Philip Philip MD, PhD, FRCP, on neoadjuvant chemotherapy & upfront surgery in pancreatic cancer

video-image

Philip Philip MD, PhD, FRCP, on promising novel therapies for pancreatic cancer

video-image

Nevena Damjanov, MD, regarding the impact of the ReDOS study in HCC

video-image

Philip Philip MD, PhD, FRCP, provides opinion on NGS and BRCA gene testing in pancreatic cancer

video-image

Nevena Damjanov, MD, elaborates on stereotactic body radiation therapy in early stage HCC

video-image

Philip Philip MD, PhD, FRCP, considers molecular subtyping of pancreatic cancer

video-image

Nevena Damjanov, MD, regarding sequencing TKIs in hepatocellular carcinoma (HCC)

video-image

Philip Philip MD, PhD, FRCP, on screening patients at high risk for pancreatic cancer

video-image

Nevena Damjanov, MD, shares thoughts on the role of systemic therapy in HCC

video-image

Jeffrey A. Meyerhardt, MD, on genetic testing in newly diagnosed mCRC

video-image

Howard Hochster, MD, on how checkpoint inhibitors are impacting treatment algorithms in mCRC

video-image

Jeffrey A. Meyerhardt, MD, shares thoughts on checkpoint inhibitors in adjuvant CRC

video-image

Howard Hochster, MD, considers next generation sequencing and mCRC treatment decisions

video-image

Jeffrey A. Meyerhardt, MD, on managing 2nd and 3rd line mCRC patients

video-image

Howard Hochster, MD, on the management of mCRC patients receiving regorafenib

video-image

Jeffrey A. Meyerhardt, MD, on whether regorafenib is becoming more tolerable for mCRC patients

video-image

Howard Hochster, MD, explains how to manage 2nd and 3rd line mCRC patients

video-image

Jeffrey A. Meyerhardt, MD, considers the BEACON study in BRAF mutated metastatic colorectal cancer

video-image

Howard Hochster, MD, regarding the role of genetic testing in mCRC

video-image

Steven J. Cohen, MD, outlines the results of the Checkmate 142 study in mCRC patients

video-image

Steven J. Cohen, MD, discusses vemurafenib and the NCCN guidelines for mCRC patients

video-image

Steven J. Cohen, MD, provides insight into sequencing and efficacy outcomes in 2nd line mCRC

video-image

Steven J. Cohen, MD, describes how tumor sidedness impacts treatment decisions in mCRC

video-image

Steven J. Cohen, MD, regarding combination atezolizumab + cobimetinib in mCRC patients

video-image

Steven J. Cohen, MD, considers the improvement in duration of therapy examined in the ReDOS study

video-image

Steven J. Cohen, MD, on how to dose patients receiving regorafenib as a result of the ReDOS study

video-image

Michael Soulen, MD, discusses the most compelling presentations from ASCO GI 2018

video-image

Michael Soulen, MD, compares the possible benefits of retrospective vs. prospective trials

video-image

Michael Soulen, MD, on the practice changing potential of data presented at his ASCO GI tumor board

video-image

Michael Soulen, MD, tells us about significant data coming out of the tumor board at ASCO GI 2018

video-image

Philip Philip, MD, PhD, FRCP, discusses the impact of the Checkmate 142 study on mCRC

video-image

Philip Philip, MD, PhD, FRCP, on the implications of the LAPACT study presented at ASCO 2018

video-image

Philip Philip, MD, PhD, FRCP, considers the impact of immunotherapy agents in pancreatic cancer

video-image

Philip Philip, MD, PhD, FRCP, regarding key unmet needs in pancreatic ductal adenocarcinoma

video-image

Nevena Damjanov, MD, shares the latest news in systemic therapy for advanced HCC at ASCO 2018

video-image

Nevena Damjanov, MD, on the use of pembrolizumab in HCC patients previously treated with sorafenib

video-image

Nevena Damjanov, MD, outlines the role of TACE with systemic therapy in HCC patients

video-image

David Ilson, MD, PhD, considers how to assess response in gastroesophageal cancer patients

video-image

Richard Kim, MD, offers opinion on the ReDOS study and dose escalation of regorafenib

video-image

Scott Kopetz, MD, PhD, FACP, on the potential of binimetinib + immunotherapy in mCRC patients

video-image

Scott Kopetz, MD, PhD, FACP, regarding molecular profile matching in trials with mCRC patients

video-image

Scott Kopetz, MD, PhD, FACP, on the implications of the BEACON Phase 3 study in BRAF-mutant mCRC

video-image

Jeffrey Meyerhardt, MD, MPH, on dose escalation of regorafenib as a result of the ReDOS study

video-image

Jeffrey Meyerhardt, MD, MPH, discusses the length of adjuvant therapy for colorectal cancer patients

video-image

Jeffrey Meyerhardt, MD, MPH, on the implications of the BEACON Phase 3 study in BRAF-mutant mCRC

video-image

Jeffrey Meyerhardt, MD, MPH, considers the addition of vemurafenib to the NCCN guidelines for mCRC

video-image

Nevena Damjanov, MD, discusses current treatment options and sequencing TKIs in HCC

video-image

Nevena Damjanov, MD, considers the shortcomings of RECIST in measuring efficacy in HCC patients

video-image

Scott Kopetz, MD, PhD, FACP, explains how nivolumab is being incorporated into mCRC treatment

video-image

Scott Kopetz, MD, PhD, FACP, tells us about the outcomes of Checkmate 142 in mCRC patients

video-image

Scott Kopetz, MD, PhD, FACP, considers the addition of vemurafenib to the NCCN guidelines for mCRC

video-image

Scott Kopetz, MD, PhD, FACP, discusses the incidence of BRAF mutation in CRC patients

video-image

Richard Kim, MD, offers analysis of the RAINFALL study in metastatic gastric & GE junction cancer

video-image

Richard Kim, MD, discusses pembrolizumab as an effective agent in HCC management

video-image

Richard Kim, MD, considers the effectiveness of combination sorafenib and TACE in HCC patients

video-image

Richard Kim, MD, on the use and sequencing of TKIs in hepatocellular carcinoma (HCC)

video-image

David Ilson, MD, PhD, examines the results of the RAINFALL study at ASCO GI 2018

video-image

David Ilson, MD, PhD, on strategies for managing gastroesophageal patients after neoadjuvant therapy

video-image

David Ilson, MD, PhD, on how we can individualize treatment of gastroesophageal cancer patients

video-image

Howard Hochster, MD, outlines the results of the Checkmate 142 study in mCRC patients

video-image

Howard Hochster, MD, considers patient age and the OncotypeDX recurrence score in CRC

video-image

Andrew Zhu, MD, PhD, on the effectiveness of pembrolizumab in HCC patients treated with sorafenib

video-image

Andrew Zhu, MD, PhD, shares thoughts on treating adjuvant hepatocellular carcinoma (HCC) today

video-image

Laura Dawson, MD, FRCPC, on additional randomized studies of external beam radiation

video-image

Laura Dawson, MD, FRCPC, tells us about the results of the START study

video-image

Laura Dawson, MD, FRCPC, discusses the design of the START study in HCC

video-image

Laura Dawson, MD, FRCPC, provides some background on hepatocellular carcinoma (HCC)

video-image

Alan Venook, MD, outlines the role of liquid biopsy in gastrointestinal cancers

video-image

Alan Venook, MD, considers how immunotherapy is being integrated into CRC treatment algorithms

video-image

Alan Venook, MD, on the impact of dose escalation of regorafenib in mCRC patients

video-image

Alan Venook, MD, discusses vemurafenib and the NCCN guidelines for mCRC patients

video-image

Alan Venook, MD, explains how tumor sidedness affects therapeutic choice

video-image

Khaldoun Almhanna, MD, MPH, offers opinion on the best way to manage early gastric cancer

video-image

Howard Hochster, MD, elaborates on how tumor sidedness affects therapeutic choice in mCRC patients

video-image

Howard Hochster, MD, on the ReDOS study, regorafenib, and the importance of duration of therapy

video-image

Andrew Zhu, MD, PhD, shares the latest in systemic therapy for advanced HCC at ASCO GI 2018

video-image

Andrew Zhu, MD, PhD, on how we diagnose and assess response in HCC patients

video-image

Howard Hochster, MD, offers opinion on the ReDOS study and dose escalation of regorafenib

video-image

Howard Hochster, MD, explains the impact of immunotherapies on gastric GE junction cancers

video-image

Howard Hochster, MD, regarding the new peri-operative regimen FLOT for gastric cancer

video-image

Philip Philip, MD, considers the benefits of immunotherapy in treating gastrointestinal cancer

video-image

Jonathan R. Strosberg, MD, discusses the results of the NETTER-1 study

video-image

Jonathan R. Strosberg, MD, discusses the quality of life data from the NETTER-1 study

video-image

John L. Marshall, MD, talks about the results of the RESORCE trial

video-image

John L. Marshall, MD, discusses which molecular tests to order when determining treatment approach

video-image

John L. Marshall, MD, on how to integrate genetic mutations into a treatment decision

video-image

John L. Marshall, MD, on how checkpoint inhibitors are being integrated into treatment of GI cancers

video-image

John L. Marshall, MD, tells us how vaccines can be used to broaden the use of immunotherapies

video-image

Jeffrey A. Meyerhardt, MD, talks about the DFCI wellness study

video-image

Philip Philip, MD, talks about treating a newly diagnosed stage 4 pancreatic cancer patient

video-image

Philip Philip, MD, on whether resected pancreatic cancer patients should be offered adjuvant therapy

video-image

Philip Philip, MD, shares his perspective on using TAS-102 and regorafenib in CRC patients

video-image

Philip Philip, MD, on which molecular tests to order for a newly diagnosed CRC patient

video-image

Philip Philip, MD, on integrating immunotherapy into existing treatment regimens for CRC patients

video-image

Alan P. Venook, MD, explains how the 80405 study and its impact on treatment guidelines

video-image

Alan P. Venook, MD, discusses which molecular tests to order for a newly diagnosed CRC patient

video-image

Alan P. Venook, MD, provides his perspective on using TAS-102 and regorafenib in CRC patients

video-image

Alan P. Venook, MD, on identifying subgroups of HCC patients that are likely to respond to therapy

video-image

Alan P. Venook, MD, on if the RESORCE trial will change the role of regorafenib

video-image

Alan P. Venook, MD, on integrating immunotherapy into treatment regimens for gastric cancer patients

video-image

Alan P. Venook, MD, on integrating immunotherapy into existing treatment regimens for HCC patients

video-image

Alan P. Venook, MD, on integrating immunotherapy into existing treatment regimens for CRC patients

video-image

Thomas A. Abrams, MD, on how checkpoint inhibitors will be incorporated into treatment of HCC

video-image

Thomas A. Abrams, MD, on reliably identifying subgroups of patients for targeted therapies in HCC

video-image

Thomas A. Abrams, MD, on whether physicians will incorporate regorafenib into clinical practice

video-image

Thomas A. Abrams, MD, discusses the outcomes of the RESORCE trial as presented here at ASCO GI 2017

video-image

Thomas A. Abrams, MD, on how new agents being studied for HCC will be integrated into the treatment

video-image

Howard S. Hochster, MD, on integrating immunotherapy into treatment regimens for GI cancer patients

video-image

Howard S. Hochster, MD, explains the outcomes of the phase 2 study in BRAF mutated CRC patients

video-image

Howard S. Hochster, MD, discusses if genetic profiling has changed treating CRC patients

video-image

Howard S. Hochster, MD, provides perspective on how to use TAS-102 and regorafenib in CRC patients

video-image

Howard S. Hochster, MD, differentiates regorafenib from 5FU and TAS-102

video-image

Ghassan Abou-Alfa, MD, discusses how checkpoint inhibitors be incorporated into the treatment

video-image

Ghassan Abou-Alfa, MD, on identifying subgroups of patients for targeted therapies in HCC

video-image

Ghassan Abou-Alfa, MD, discusses if regorafenib will be incorporated into clinical practice

video-image

Ghassan Abou-Alfa, MD, discusses the outcomes of the RESORCE trial

video-image

Ghassan Abou-Alfa, MD, explains how new agents in advanced HCC are being integrated into treatment

video-image

Nevena Damjanov, MD, explains how checkpoint inhibitors will be incorporated into the treatment

video-image

Nevena Damjanov, MD, discusses identifying subgroups of patients for targeted therapies in HCC

video-image

Nevena Damjanov, MD, on whether regorafenib will be integrated into clinical practice

video-image

Nevena Damjanov, MD, explains the outcomes of the RESORCE trial as presented here at ASCO GI 2017

video-image

Nevena Damjanov, MD, discusses how new agents for advanced HCC will be integrated into the treatment

video-image

Johanna Bendell, MD, talks about the Proprietary Neoantigen Identification Technology platform

video-image

Johanna Bendell, MD, discusses the RESORCE trial data

video-image

Johanna Bendell, MD, discusses some of the challenges in treating pancreatic cancer

video-image

Johanna Bendell, MD, on some of the exciting trials or drugs in development in pancreatic cancer

video-image

Johanna Bendell, MD, talks about the phase 3 study in advanced gastric or GE junction presented at ASCO GI 2017

video-image

Jeffrey A. Meyerhardt, MD, discusses outcomes of the phase 2 study in BRAF mutated CRC patients

video-image

Jeffrey A. Meyerhardt, MD, discusses how consensus molecular subtypes help with CRC treatment

video-image

Jeffrey A. Meyerhardt, MD, explains which molecular tests help determine treatment approach

video-image

Jeffrey A. Meyerhardt, MD, on integrating immunotherapy into treatment regimens for GI cancer

video-image

Edith P. Mitchell, MD, discusses the goals of the NCI-MATCH trial and the progress to date

video-image

Edith P. Mitchell, MD, on how the Blue Ribbon Panel may help with the Cancer Moonshot initiative

video-image

Edith P. Mitchell, MD, discusses integrating immunotherapy into treatment regimens for CRC patients

video-image

Edith P. Mitchell, MD, explains how organoids are being used for cancer biology research

video-image

Richard M. Goldberg, MD, discusses the gastric cancer treatment algorithm based on the CRITICS study

video-image

Choosing which EGFR inhibitor to use in second line treatment of mCRC patients At ASCO GI 2016

video-image

TAS-102 versus 5-flourouracil and other more familiar agents ASCO GI 2016

video-image

RECOURSE versus CORRECT and CONCUR trials evaluating regorafenib in metastatic CRC at ASCO GI 2016

video-image

RECOURSE trial did performance status impact benefit from TAS-102 at ASCO GI 2016

video-image

Integrating TAS-102 and regorafenib into your therapeutic algorithm for advanced CRC at ASCO GI 2016

video-image

Design of the RECOURSE trial on which the FDA approved TAS-102

video-image

RECOURSE trial compared to CORRECT and CONCUR evaluating regorafenib in mCRC

video-image

Biggest questions facing the treatment of colorectal cancer ASCO GI 2016

video-image

How has the last 10 years changed the way you treat metastatic colorectal cancer ASCO GI 2016

video-image

Immunotherapy, MET, and HER 2+ research is the future of colorectal cancer treatment ASCO GI 2016

video-image

Potential cases to use Regorafenib over TAS-102 ASCO GI 2016

video-image

Regorafenib experience and integrating TAS-102 for advanced CRC ASCO GI 2016

video-image

More money should be allocated to early detection and screening in colorectal cancer ASCO GI 2016

video-image

PD-L1 markers in MMR deficient cancers ASCO GI 2016

video-image

Mismatch Repair (MMR) deficient and the use of PD-1 blockade ASCO GI 2016

video-image

ERCC1 not a valid prognostic or predictive factor in advanced CRC ASCO GI 2016

video-image

Planned studies to evaluate immune checkpoint inhibitors in MMR deficient GI cancers ASCO Gi 2016

video-image

STEAM trial may not change treatment paradigm for metastatic CRC ASCO 2016

video-image

RAS mutation in patients with metastatic colorectal cancer ASCO GI 2016

video-image

Does the Asian population differ from the western populations in regards to gastric cancers

video-image

The future of gastric cancers will be targeted agents including immunotherapy

video-image

FOLFOX + ziv-aflibercept placebo adding anti-angiogenic agent to chemotherapy in advanced gastric and GE junction adenocarcinoma

video-image

Phase II-III trial results T-DM1 in previously treated gastric and GE junction adenocarcinoma

video-image

GATSBY trial results T-DM1 in previously treated gastric and GE junction adenocarcinoma at ASCO GI 2016

video-image

FOLFOX + ziv-aflibercept v. AVAGAST trial of capecitabine-cisplatin with or without bevacizumab in gastric carcinomas at ASCO GI 2016

video-image

ASCO GI 2016 Optimal Dosage Using Regorafenib Colorectal Cancer

video-image

Managing patients on regorafenib including adverse events

video-image

Next steps for checkpoint inhibitors after Checkmate-032 and KEYNOTE-028 trials in UGI malignancies

video-image

KEYNOTE-028 results with pembrolizumab

video-image

Pembrolizumab looks promising according to KEYNOTE-028 results

video-image

Immunotherapy Shows Promise in MSI-High Colorectal Cancer

video-image

Pancreatic Cancer News from ASCO GI 2016

video-image

Weekly T-DM1 surprising or disappointing ASCO GI 2016

video-image

Future of TAS-102 and regorafenib for patients with colorectal cancer

video-image

TAS-102 and how it differ from more familiar agents, such as 5-flourouracil, capecitabine and S-1

video-image

RECOURSE trial versus CORRECT and CONCUR trials evaluating regorafenib

video-image

Importance of performance status prior to starting regorafenib at ASCO GI 2016